Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 4/20 | 0.52 |
| ▸ | BRAF | P15056 | 9/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 3/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30161531 | 0.84 | SLC40A1 (0.52) | SLC40A1BRAFCYP3A4GLO1CYP2C9 | |
| SCHEMBL25450267 | 0.84 | SLC40A1 (0.52) | SLC40A1BRAFCYP3A4GLO1CYP2C9 | |
| SCHEMBL1492012 | 0.83 | SLC40A1 (0.52) | SLC40A1CYP2C9 | |
| SCHEMBL1462153 | 0.83 | SLC40A1 (0.52) | SLC40A1CYP2C9 | |
| SCHEMBL3029913 | 0.82 | CYP3A4 (0.56) | SLC40A1BRAFCYP3A4GLO1CYP2C9 | |
| SCHEMBL21047044 | 0.78 | BRAF (0.62) | SLC40A1BRAFCYP3A4GLO1CYP2C9 | |
| SCHEMBL21046856 | 0.78 | BRAF (0.70) | BRAF | |
| SCHEMBL3020516 | 0.78 | BRAF (0.49) | BRAFCYP3A4CYP2C9BRD4 | |
| SCHEMBL21046838 | 0.78 | BRAF (0.70) | BRAF | |
| SCHEMBL21046790 | 0.77 | BRAF (0.60) | SLC40A1BRAFGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | claimed |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-11-09 | — | — | US | claimed |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-03-02 | — | — | US | claimed |
| EP-2170830-B1 | 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS | PLEXXIKON INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-18 | — | — | US | disclosed |
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2019-06-13 | — | — | US | disclosed |
| US-9844539-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2017-03-02 | — | — | US | disclosed |
| US-20140303187-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140038948-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130237531-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2013-09-12 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2010-07-29 | — | — | US | disclosed |
| EP-2170830-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009012283-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346358-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | SLC40A1 3103/4885BRAF 1/4885CYP3A4 3611/4885 |
| US-20130237531-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
| US-20210353602-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
| US-20140303187-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
| US-20100190777-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K11, MAP3K10 | SLC40A1 4195/4885BRAF 25/4885CYP3A4 3607/4885 |
| US-10426760-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
| US-20190209536-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
| US-20190175567-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
| US-20170319559-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
| US-20140038948-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
| US-20170056382-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | SLC40A1 4554/4885BRAF 48/4885CYP3A4 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.